Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial-Reference-Cited by-同舟云学术

Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

Published:2022-10-24 Issue:2 Volume:112 Page:330-332
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Ferreira João Pedro^ORCID,Cleland John G. F.,Girerd Nicolas,Pellicori Pierpaolo,Hazebroek Mark R.,Verdonschot Job,Collier Timothy J.,Petutschnigg Johannes,Clark Andrew L.,Staessen Jan A.,Heymans Stephane,Zannad Faiez,Rossignol Patrick

Funder

FP7 Science in Society

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00392-022-02116-w.pdf

Reference10 articles.

1. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51–58. https://doi.org/10.1161/circheartfailure.113.000792

2. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60:2082–2089. https://doi.org/10.1016/j.jacc.2012.07.048

3. Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O’Meara E et al (2021) Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol 77:1211–1221. https://doi.org/10.1016/j.jacc.2020.12.057

4. Rossignol P, Hernandez AF, Solomon SD, Zannad F (2019) Heart failure drug treatment. Lancet 393:1034–1044. https://doi.org/10.1016/s0140-6736(18)31808-7

5. Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP et al (2020) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart “OMics” in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa758

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease;Clinical Journal of the American Society of Nephrology;2024-07-22

2. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases;Nephrology Dialysis Transplantation;2024-01-08

3. Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study;Pharmaceuticals;2023-09-14

4. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE;European Journal of Heart Failure;2023-08-22

5. Prognosis and personalizedin-silicoprediction of treatment efficacy in cardiovascular and chronic kidney disease: a proof-of-concept study;2023-08-06